- Report
- August 2024
- 161 Pages
Global
From €2290EUR$2,500USD£1,949GBP
- Report
- April 2025
- 106 Pages
Global
From €4350EUR$4,750USD£3,704GBP
- Report
- May 2024
- 145 Pages
Global
From €3617EUR$3,950USD£3,080GBP
- Report
- March 2025
- 1400 Pages
Global
From €4488EUR$4,900USD£3,821GBP
- Report
- February 2025
- 148 Pages
Global
From €3998EUR$4,365USD£3,403GBP
€4442EUR$4,850USD£3,782GBP
- Report
- March 2025
- 260 Pages
Middle East
From €2656EUR$2,900USD£2,261GBP
- Report
- March 2025
- 210 Pages
Latin America
From €2656EUR$2,900USD£2,261GBP
- Report
- March 2025
- 840 Pages
Asia Pacific
From €2656EUR$2,900USD£2,261GBP
- Report
- March 2025
- 260 Pages
Africa
From €2656EUR$2,900USD£2,261GBP
- Report
- March 2025
- 980 Pages
Europe
From €2656EUR$2,900USD£2,261GBP
- Report
- February 2025
- 236 Pages
United States
From €7322EUR$7,995USD£6,234GBP
- Report
- August 2022
- 120 Pages
Global
From €3526EUR$3,850USD£3,002GBP
€5037EUR$5,500USD£4,288GBP
- Report
- July 2023
- 220 Pages
Global
From €1822EUR$1,990USD£1,552GBP
- Report
- August 2024
- 120 Pages
Russia
From €5449EUR$5,950USD£4,639GBP
- Report
- April 2021
China
From €2381EUR$2,600USD£2,027GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4350EUR$4,750USD£3,704GBP
- Report
- November 2023
- 30 Pages
Global
From €2519EUR$2,750USD£2,144GBP
- Report
- November 2023
- 30 Pages
Global
From €2519EUR$2,750USD£2,144GBP
- Report
- January 2022
- 90 Pages
Global
From €1832EUR$2,000USD£1,559GBP
- Report
- May 2023
- 160 Pages
Global
From €4532EUR$4,949USD£3,859GBP

The Human Insulin market is a segment of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Human Insulin is a synthetic form of insulin, which is produced in a laboratory and is identical to the insulin produced by the human body. It is used to treat both type 1 and type 2 diabetes. Human Insulin is available in a variety of forms, including short-acting, intermediate-acting, and long-acting. It is typically administered via injection or an insulin pump.
Some companies in the Human Insulin market include Novo Nordisk, Sanofi, Eli Lilly, and Biocon. Show Less Read more